key: cord-0720248-ntozf7ba
authors: Copertino, Dennis C.; Duarte, Rodrigo R. R.; Powell, Timothy R.; de Mulder Rougvie, Miguel; Nixon, Douglas F.
title: Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
date: 2020-07-19
journal: J Med Virol
DOI: 10.1002/jmv.26299
sha: 048c66fc10d16dc1ee6c5dbc6125b6a14cab14fb
doc_id: 720248
cord_uid: ntozf7ba

COVID-19 presents a major worldwide public health emergency. Many research efforts are ongoing to find effective antiviral treatments via novel drug design or drug repurposing (Duarte et al., 2020). One drug, remdesivir, has been shown to have activity against the SARS-CoV-2 RNA dependent RNA polymerase (RdRp), and has been used clinically in severe COVID-19 disease, but more accessible and readily available treatments are needed for all stages of infection. This article is protected by copyright. All rights reserved.

Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

To the Editor, Coronavirus disease 2019 (COVID-19) presents a major worldwide public health emergency. Many research efforts are ongoing to find effective antiviral treatments via novel drug design or drug repurposing. 1 One drug, remdesivir, has been shown to have activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA dependent RNA polymerase (RdRp), and has been used clinically in severe COVID-19 disease, but more accessible and readily available treatments are needed for all stages of infection.

Two recent reports discussed both anecdotal positive clinical benefits and the potential for off-label use of the drug montelukast in certain patients with COVID-19, 2,3 which led us to investigate its potential anti-SARS-CoV-2 properties in silico. Montelukast had previously been shown to have antiviral activity against ZIKA and dengue viruses, 4 as well as immune modulatory properties. We hypothesized that montelukast might have antiviral activity against SARS-CoV-2, and act as an anti-inflammatory agent effective against exuberant immune activation in COVID-19 disease. Montelukast had been shown to inhibit macrophage M2 related cytokines, acting as a cysteinyl leukotriene receptor antagonist. 5 It can also protect against Influenza A virus induced pneumonia by reducing infection of type-1 alveolar epithelial cells and modulating other proinflammatory mediators. 6 In a rat model, montelukast lowered TNF-alpha and interleukin-6, increased glutathione and superoxide dismutase 7 and lowered mortality related to sepsis. The cytokine storm in COVID-19 is at least partially caused by mast cell activation, and leukotriene receptor antagonists like montelukast could also be used for their ability to attenuate mast cell activation. 8 We undertook an in silico molecular docking analysis to simulate binding of montelukast to catalytically active sites within the SARS-CoV-2

Main protease (Mpro) and RNA dependent RNA polymerase (RdRp).

If montelukast could bind to key residues typically required for the enzymatic activity of these proteins, and effectively inhibit the activity of the Mpro, it should be able to disrupt the substrate binding site. We were specified as the catalytically active sites by Zhang et al. 10 and Gao et al. 11 The resulting protein-ligand scores (PLANTS scores) were calculated using the empirical scoring algorithm CHEMPLP, 9 and reflect the energy change when ligands and proteins come together, with values more negative than (−91.00) suggesting likely protein-ligand interactions. 12, 13 All other docking parameters and forcefields are noted in our previous work. 13 Protein-ligand structures were visualized using The accumulation of data on the drug montelukast, including the data presented here, it's known antiviral activity 4 and immunomodulation, [5] [6] [7] [8] along with anecdotal evidence in patients with COVID-19, 2 suggests a repurposing potential for montelukast in the treatment of COVID-19.

We would like to caution readers that, despite the in silico evidence described here, there is no robust evidence yet that montelukast will be an effective treatment for COVID-19. Montelukast is used for allergic rhinitis and now off-label for COVID-19, however physicians are ultimately responsible for prescribing drugs like montelukast. There is a Blackbox warning for the use of montelukast, noting serious mental health side-effects. However, our studies suggest that further investigation into the role of montelukast in SARS-CoV-2 prevention or COVID-19 amelioration is warranted. to key residues of the viral enzymes. The red dots indicate the designated catalytic sites for the purpose of this study. The binding and potential inhibition of these enzymes would disrupt the replication machinery of this virus, as shown by the schematic. The image in Figure 1 was created using BioRender F I G U R E 2 Image of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA dependent RNA polymerase (RdRp) enzyme (left), and Main protease (Mpro) of SARS-CoV-2 (right). Montelukast is shown docked to each viral enzyme's catalytic site separately

The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast

Montelukast, an anti-asthmatic drug, inhibits Zika virus infection by disrupting viral integrity. Front Microbiol

Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages

Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells

The effects of montelukast on antioxidant enzymes and proinflammatory cytokines on the heart, liver, lungs, and kidneys in a rat model of cecal ligation and punctureinduced sepsis

The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress

Empirical scoring functions for advanced protein-ligand docking with PLANTS

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

LEA3D: a computer-aided ligand design for structure-based drug design

Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection